1. The Future of Cresset? Dr Robert Scoffin Chief Executive Officer

2. Customer Thanks You are the reason we are here Our motivation is to create the best possible tools to aid drug discovery Your input drives future developments Your financial support enables us to keep the lights on You are also the reason we will be here next year Our ongoing commitment to maintaining the high quality of our solutions Focus on innovation in both science and service Returning value for your investment in us

3. 2010-2011 Year In Review Cresset Business grew 25% from 2009 to 2010 Continued growth in 2011 – projecting > 35% 2010 to 2011 Strong additions to the team – Mike, Rae, Viv, Janany, Chris, Martin, Rachel. Science Extension of FieldAlign with 3D-QSAR methodology On-going development of new application for ‘Molecular Designers’ Extended applications in peptide mimetics, drug re-profiling, etc. Portfolio Expansion Extended Professional Services/Consulting offerings – driven by Martin Slater, backed up by Chris Earnshaw, Andy, Rob, Tim & Mark Software-as-a-Service (SaaS) offering of FieldScreen (initially – others to follow)

4. Diverse Cresset Users Medicinal Chemists Molecular Modellers

5. Strategy for Growth Consolidate our position in existing markets Strengthen current tools Look for other applications we can build on the existing science Further expand the science base of Cresset Develop New Markets Med. Chem focus through new applications New users for existing technology: Patenting, In-Licencing, ADMET, etc. Expanded Services Offerings Consulting services around use of the applications New delivery platforms for existing applications

6. New delivery platforms The latest addition to the Cresset team The Cresset cow Cluster On Wheels Portable, on-demand computing infrastructure Pre-loaded FieldScreen application and database Plug-in and go capacity expansion Secure – data on portable, removable drives The Cresset COW

7. Scientific Focus FF3 Free Dr Vinter up from mundane day-to-day activities to focus on completing FF3 Extensive validation and testing cycle – aim to release in 2012 Re-Profiling/Re-Purposing Extend applications in drug re-profiling TSB funded project with Biolauncher to build re-profiling database and toolkits Massively parallel computing New initiative to re-code Cresset tools (initially FieldScreen, others to follow) to run on GPU’s OpenCL implementation of the scoring functions Fields/Field points on proteins Further investigation and application of Field approach to protein surfaces and structures

8. May the Force (field) be with you… There’s a disturbance in the Nitrogen force When will FF3 be ready?

9. Scientific Focus FF3 Free Dr Vinter up from mundane day-to-day activities to focus on completing FF3 Extensive validation and testing cycle – aim to release in 2012 Re-Profiling/Re-Purposing Extend applications in drug re-profiling TSB funded project with Biolauncher to build re-profiling database and toolkits Massively parallel computing New initiative to re-code Cresset tools (initially FieldScreen, others to follow) to run on GPU’s OpenCL implementation of the scoring functions Fields/Field points on proteins Further investigation and application of Field approach to protein surfaces and structures

10. Ridley Scott’s Tribute to Andy Tyrell: The light that burns twice as bright burns for half as long - and you have burned so very, very brightly, Roy Andy. Look at you: you're the Prodigal Son; you're quite a prize! Batty: I've done... questionable things. Tyrell: Also extraordinary things; revel in your time. Andy Vinter Batty: Nothing the God of biomechanicsdrug discovery wouldn't let you into heaven for.

11. rob@cresset-group.com Questions welcomed